Data presented in NeuroCritic Care society 19e Annual meeting 2021
Data show changes in diagnosis of Daxor in 69% of patients With No-Traumatic subarachnoid hemorrhage (nSAH)
NEW YORK, November 09, 2021 (GLOBE NEWSWIRE) – Daxor company (NYSE MKT: DXR), Global Leader in Blood Volume Measurement Technology, Today Announces New Data Demonstrating the Clinical Utility of the BVA-100 Blood Test in Patients with Non-traumatic Subarachnoid Hemorrhage (NSAH) Presented at the Virtual NeuroCritical Care Society (NCS) 19e Annual meeting.
The study “The Influence of Blood Volume Analysis on the Clinical Management of Nontraumatic Subarachnoid Hemorrhage” investigated whether intravascular volume assessments would influence clinical decision making in nSAH. The data showed that 69% responded with different management strategies after receiving the BVA results. Lindsey Carvalho MD, Principal Investigator, concluded: âAll participants indicated a preference for AVB over invasive hemodynamic monitoring if they had the option to monitor volume status in nSAH due to the lesser nature. invasive from the first. “
Previous research presented to NCS in 2020 titled “Blood Volume Analysis in the Management of Volume Status in Nontraumatic Subarachnoid Hemorrhage,” investigated whether BVA would change clinical practice guidelines for the management of nSAH to prevent delayed cerebral ischemia (CDI) during high-risk periods. Of the completed BVA tests, 54% resulted in a change in treatment management after interpretation of the BVA test results.
âNon-traumatic subarachnoid hemorrhage can cause complicated and irreversible neurological damage and achieving optimal intravascular volume plays an important role in improving patient outcomes,â said Michael Feldschuh, CEO and President of Daxor Corporation. âThese new data further demonstrate that Daxor’s unique blood volume measurement helps physicians effectively determine treatment options for managing water disorders for these critically ill patients and is the driving force behind this test for standard clinical practice. “
Previous data in the area of ââICU surgical management have shown an equally high level of BVA-100 testing leading to a change in treatment strategy. In a randomized controlled trial (RCT) published in the journal Shock, the BVA-100 test was shown to reduce ICU mortality by 66% (P = 0.03) and on ventilation days in patients with predominantly acute respiratory distress syndrome and septic shock. Additionally, analysis showed that 44% of BVA test results led to a change in treatment strategy (P = 0.004) that healthcare teams would not have made without the condition measurement data. of the BVA volume.
On Daxor company
Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on innovation in blood volume testing (organized as an investment firm with medical instrumentation and biotechnology operations innovative wholly-owned). We have developed and marketed the BVA-100Â® (Blood Volume Analyzer), the first diagnostic blood test approved by the FDA to provide safe, accurate and objective quantification of blood volume status and composition against patient-specific standards. BVA technology improves hospital performance measures in a wide range of surgical and medical conditions, including heart failure and intensive care, by informing treatment strategies, resulting in multiple dramatically improved outcome measures for the patients. Daxor’s mission is to advance healthcare by enabling optimal fluid management through blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Certain statements contained in this press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the impact of hiring sales personnel and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements regarding future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. There are many factors that could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, the risks associated with our post-market clinical data collection activities, the benefits of our products for patients, our expectations in terms of product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding expected synergies and benefits from acquired businesses, and other additional risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date on which they are made. Daxor assumes no obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Senior Managing Partner, CORE IR